Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

150.84USD
18 Mar 2019
Change (% chg)

$-0.41 (-0.27%)
Prev Close
$151.25
Open
$151.96
Day's High
$152.79
Day's Low
$150.56
Volume
680,697
Avg. Vol
709,702
52-wk High
$197.00
52-wk Low
$125.84

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

Financials

  AGN.N Industry Sector
P/E (TTM): -- 29.30 32.54
EPS (TTM): -11.66 -- --
ROI: -3.08 14.23 13.82
ROE: -5.61 15.46 15.25

Appaloosa steps up pressure on Allergan after failed drug trials

Hedge fund Appaloosa LP on Thursday repeated its call for an independent chairman at Allergan Plc, after the Botox producer revealed that one of its drugs had failed three clinical studies.

Mar 07 2019

UPDATE 1-Appaloosa steps up pressure on Allergan after failed drug trials

March 7 Hedge fund Appaloosa LP on Thursday repeated its call for an independent chairman at Allergan Plc , after the Botox producer revealed that one of its drugs had failed three clinical studies.

Mar 07 2019

Appaloosa steps up pressure on Allergan after failed depression drug trials

March 7 Hedge fund Appaloosa LP on Thursday reiterated its call for an independent chairman at Allergan Plc's board, after the Botox-maker said its depression treatment failed three late-stage studies.

Mar 07 2019

Allergan depression treatment fails studies, shares slip

Allergan Plc said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker's shares down nearly 4 percent after the bell.

Mar 06 2019

UPDATE 2-Allergan depression treatment fails studies, shares slip

March 6 Allergan Plc said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker's shares down nearly 4 percent after the bell.

Mar 06 2019

Allergan's add-on treatment for depression fails late-stage studies

March 6 Allergan Plc said on Wednesday its experimental add-on treatment for major depressive disorder failed to meet the main goals of three late-stage studies.

Mar 06 2019

Allergan shareholder Chevedden backs Appaloosa's proposal to split CEO-chairman role

Appaloosa LP said on Thursday investor John Chevedden was backing the hedge fund's proposal to split the roles of chairman and chief executive officer at Botox-maker Allergan Plc.

Feb 28 2019

UPDATE 1-Allergan shareholder Chevedden backs Appaloosa's proposal to split CEO-chairman role

Feb 28 Appaloosa LP said on Thursday investor John Chevedden was backing the hedge fund's proposal to split the roles of chairman and chief executive officer at Botox-maker Allergan Plc.

Feb 28 2019

Allergan shareholder Chevedden backs Appaloosa's proposal to split CEO-chairman role

Feb 28 Appaloosa LP said on Thursday minority investor John Chevedden was backing the hedge fund's proposal to split the roles of chairman and chief executive officer at Botox-maker Allergan Plc.

Feb 28 2019

Allergan should explore selling itself: Appaloosa's Tepper

Billionaire hedge fund manager David Tepper stepped up pressure on Allergan Plc, saying on Tuesday the drugmaker should consider selling itself if management is unable to turn around recent lagging performance.

Feb 19 2019

Earnings vs. Estimates